The Diagnosis & Management of Asthma in Adults

Objectives

The guideline provides an evidence-based national framework for diagnosing, assessing and managing asthma in adults aged over 18 years in Qatar across primary and secondary care. It aims to improve asthma control, prevent avoidable deaths, hospitalisation and permanent lung-function impairment, reduce inappropriate prescribing and referral, and support quality of life, normal activity and exercise with the minimum effective medication.[1][2][3][4][5][6]It excludes asthma management in children and pregnancy.[1]

• Standardise diagnosis through structured history, examination and objective assessment of variable airflow obstruction, using spirometry as the preferred initial test and peak expiratory flow only when spirometry is unavailable.[7][8]
• Improve access to spirometry in primary care and relevant outpatient clinics, and consider dedicated asthma clinics within primary healthcare.[9][8][10]
• Identify occupational asthma promptly in working-age people with airflow-limitation symptoms, while avoiding diagnosis based on history alone because of potential employment implications.[9][11][4]
• Manage acute exacerbations according to the most severe observed clinical features, with early escalation for severe, life-threatening or near-fatal presentations.[12][13][14]
• Promote long-term control through personalised education, written asthma action plans, trigger management, adherence support, correct inhaler technique and stepwise treatment adjustment.[14][10][5][6]
• Maintain treatment at the lowest effective step, escalating therapy when control is inadequate and considering step-down after a stable period.[5][6][15]
• Reserve specialist therapies, including biological treatment, immunotherapy and bronchial thermoplasty, for selected patients with severe or difficult asthma in appropriately experienced services.[2][16][15]

Implementation

The Ministry of Public Health developed and issued the guideline through an evidence-review, localisation and multidisciplinary governance process, for use principally by physicians in primary care and outpatient settings while supporting care across primary and secondary services.[1][17]Recommendations draw on systematically searched and critically appraised medical literature, established international guidelines and evidence grading, with regular updating intended to incorporate stakeholder feedback from across Qatar.[1][18][17]

• Govern development through a Guideline Development Group comprising practising healthcare professionals, subject-matter experts and patient representatives, alongside review and approval by the Ministry-appointed National Clinical Guidelines and Pathways Committee.[1][18][9]
• Manage conflicts of interest through member declarations reviewed and retained by the Ministry of Public Health.[18][9]
• Deliver diagnosis through symptom assessment, clinical examination, spirometry and reversibility testing, with further investigations or specialist referral where results are inconclusive or alternative diagnoses are possible.[8][19][11]
• Investigate suspected occupational asthma using questions about improvement away from work, serial peak expiratory flow measurement at and away from work, appropriate allergy testing and specialist advice where uncertainty remains.[11][4]
• Provide severity-based community and Emergency Department treatment for acute asthma, including oxygen, inhaled bronchodilators, corticosteroids, reassessment and escalation to continuous nebulisation, intravenous magnesium sulphate, ward admission or intensive care where clinically indicated.[13][20][14]
• Discharge acute-care patients only after a good response and at least 60 minutes of clinical stability, then provide corticosteroid and inhaled treatment as appropriate, check inhaler technique, communicate discharge information to primary care within 24 hours and arrange primary-care follow-up within two days.[14]
• Provide routine primary-care review at least annually, with closer monitoring for people with poor lung function or a recent asthma attack, including symptom control, attacks, lung function, reliever use, adherence, inhaler technique, triggers, lifestyle and vaccination status.[10][5][6]
• Use personalised self-management education and regularly reviewed written action plans, with telemonitoring, automated reminders and computer-based educational tools available as supportive options.[10]
• Refer patients with unclear diagnosis, suspected occupational asthma, poor treatment response, severe attacks or persistent symptoms despite advanced treatment to asthma-specialised physicians or multidisciplinary difficult-asthma services.[16][15][21]
• Initiate omalizumab and bronchial thermoplasty only through specialist respiratory services with expertise in severe and difficult asthma; assess omalizumab response at 16 weeks, and apply specific governance, consent and audit or research arrangements to bronchial thermoplasty.[15]
• Apply person-centred care by protecting dignity, privacy and confidentiality, supporting informed consent and shared decision making, adapting communication to individual needs and ensuring continuity of information during care transitions.[22]

Monitoring & Evaluation

Monitoring combines clinical assessment across acute and chronic care with a limited set of provider-concordance measures. The guideline does not set out a comprehensive national surveillance, reporting or audit framework in the supplied material, but it specifies review processes, clinical monitoring intervals, documentation requirements and governance safeguards.[14][10][22]

• Monitor acute exacerbations in Emergency Departments through symptoms, treatment response, heart rate, respiratory rate, oxygen saturation and peak expiratory flow at 15-minute intervals for severe and mild-to-moderate presentations.[20]Assess life-threatening cases with blood gases and chest radiography, and consider potassium and glucose testing, with repeat arterial blood gas measurement where indicated.[20]
• Use treatment response, peak expiratory flow, clinical stability and at least 60 minutes of observation to determine discharge, continued treatment, ward admission, intensive care admission or transfer.[13][20]Discharge information should be communicated electronically or by fax to the primary care physician within 24 hours.[14]
• Review patients after an acute attack in primary care within two days, including symptoms, peak expiratory flow, medication, inhaler technique, adherence, trigger exposure, education and the written asthma action plan.[14]
• Conduct routine asthma review at least annually, with closer monitoring for people with poor lung function or an asthma attack during the preceding year.[10]Record symptom control using recognised criteria or tools such as the Asthma Control Questionnaire and Asthma Control Test, and record attacks, oral corticosteroid use and time off work.[10]
• Assess lung function by spirometry or peak expiratory flow at diagnosis, after three to six months, and thereafter every three to 12 months according to asthma control.[10]Use spirometry with reversibility testing to support diagnosis, recognising that normal results in an asymptomatic person do not exclude asthma.[8]
• Review inhaler technique and self-management plans at least annually, while monitoring adherence, bronchodilator reliance, prescription refill frequency, medication side effects, trigger exposure and device suitability.[10][5]Urgently assess patients prescribed more than one short-acting bronchodilator inhaler each month.[6]
• Monitor serum lactate when continuous salbutamol nebulisation is used because of potential toxicity.[14]Monitor oral corticosteroid treatment for reduced bone mineral density, raised blood pressure, dyslipidaemia, diabetes mellitus and cataracts.[16]
• Review omalizumab effectiveness at 16 weeks and continue treatment only where there has been marked improvement.[15]Apply clinical governance, informed-consent and audit or research arrangements where bronchial thermoplasty is used.[15]

Provider concordance is measured through indicators AA01 to AA06, using defined numerators and denominators for adults with asthma. These measures cover annual asthma-control reviews, diagnosis documentation, occupational-cause assessment, provision of personalised action plans before discharge, timely steroid treatment for severe exacerbations and Emergency Department attendance.[22]

Recommendations are based on reviewed medical literature and an evidence hierarchy spanning systematic reviews, meta-analyses and randomised controlled trials through observational evidence and expert opinion.[1][18]The Guideline Development Group and National Clinical Guidelines & Pathways Committee reviewed the guideline, while members’ conflict-of-interest declarations were reviewed and retained by the Ministry of Public Health.[18][9]The published version was dated 22 August 2019, with revision scheduled for 22 August 2021.[23]

The supplied material does not specify national reporting frequencies, data systems, surveillance arrangements, named audit leads, performance targets, sanctions or a wider formal accountability mechanism beyond the listed clinical reviews, performance measures and governance processes.[18][9][22]

Costing & Financing

No explicit budget, programme cost, funding source, financing mechanism, resource-mobilisation plan, funding gap or economic assumption is provided in the supplied extracts.[1][18][9][24][16][22]

• Identify service-resource implications without assigning costs, including access to spirometry in primary and outpatient clinics, consideration of dedicated asthma clinics, specialist centres for severe and difficult asthma, multidisciplinary difficult-asthma services, Emergency Department observation capacity and intensive care escalation for critical cases.[9][15][21]
• Support delivery through clinical resources such as inhaled and systemic medicines, peak-flow measurement, oxygen, blood-gas testing, radiography, patient education, written action plans, electronic or faxed discharge communication and primary-care follow-up.[20][14][10]
• Use goal lengths of stay, where included, only after validation through utilisation analysis of international health-insurance databases to judge whether inpatient-duration benchmarks are reasonable and clinically appropriate.[1]The guideline identifies an optimal inpatient stay of one to two days in one acute-care section and one day in a later admission-focused section, but does not provide a monetary valuation or funding basis for either benchmark.[2][25]
• Limit specialist interventions to appropriately experienced settings, including omalizumab initiation and bronchial thermoplasty, but the extracts provide no procurement, reimbursement, affordability or cost-effectiveness information for these treatments.[15]

Accordingly, the document supports resource planning through clinical service specifications rather than through an explicit financial plan. The supplied material does not quantify workforce, equipment, medicine, facility or information-system requirements.[1][15][22]